Product Name: 5-bromo-2-chloro-4-ethoxydiphenylmethane CAS NO: 461432-23-5
4-(5-Bromo-2-chlorobenzyl)phenyl ethyl ether;
Chemical & Physical Properties:
Appearance :white powder
Boiling Point:393℃ at 760 mmHg
Dapagliflozin is a sodium-glucose cotransporter 2 inhibitor. The US Food and Drug Administration (FDA) announced on January 8, 2014 that it approved dapagliflozin for the treatment of type 2 diabetes and required Manufacturers conduct post-market research on drug-related risks. Post-marketing trials required by the FDA include a cardiovascular outcome trial that assesses the cardiovascular risk of high-risk cardiovascular disease patients treated with dapagliflozin at baseline and a study that assesses the risk of bladder cancer in recruited patients. Another study will evaluate the drug's bladder tumor promotion effect in rodents. Two studies will evaluate the pharmacokinetics, efficacy, and safety of dapagliflozin in pediatric patients; an enhanced pharmacovigilance program will monitor liver abnormalities and pregnancy outcome reports in patients treated with dapagliflozin. Dapagliflozin will be sold by Haoeyou Pharmacy under the trade name Farxiga.
If you are interested in our products or have any questions, please feel free to contact us!
Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.